Cutia Therapeutics reported revenue results for the third quarter of 2023 and Nine Months Ended 30 September 2023. In the third quarter of 2023, revenue of the Group ' s commercialized products amounted to approximately RMB 30.5 million, representing a positive growth of approximately 595.0% as compared to the same period in 2022.

For the nine months ended 30 September 2023, revenue of the Group's commercialized products amounted to approximately RMB 64.8 million, representing a positive growth of approximately 1,185.8% as compared to the same period in 2022.